Grimes & Company Inc. lowered its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 19.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 43,524 shares of the company’s stock after selling 10,361 shares during the period. Grimes & Company Inc.’s holdings in Teva Pharmaceutical Industries were worth $2,186,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Investec Asset Management LTD raised its position in shares of Teva Pharmaceutical Industries by 112.4% in the first quarter. Investec Asset Management LTD now owns 2,171,655 shares of the company’s stock worth $116,205,000 after buying an additional 1,148,997 shares during the last quarter. Bridger Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth about $59,320,000. TIAA CREF Investment Management LLC raised its position in shares of Teva Pharmaceutical Industries by 51.4% in the first quarter. TIAA CREF Investment Management LLC now owns 2,485,296 shares of the company’s stock worth $132,988,000 after buying an additional 843,358 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Teva Pharmaceutical Industries by 123.7% in the first quarter. Renaissance Technologies LLC now owns 1,191,263 shares of the company’s stock worth $63,744,000 after buying an additional 658,763 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in shares of Teva Pharmaceutical Industries by 26.1% in the first quarter. UBS Asset Management Americas Inc. now owns 3,015,673 shares of the company’s stock worth $161,368,000 after buying an additional 624,629 shares during the last quarter.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded up 0.24% during midday trading on Wednesday, reaching $50.48. The company had a trading volume of 3,351,448 shares. The company’s 50-day moving average is $52.18 and its 200-day moving average is $53.27. The firm has a market cap of $46.14 billion, a P/E ratio of 33.72 and a beta of 0.82. Teva Pharmaceutical Industries Ltd has a 52-week low of $48.01 and a 52-week high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.05. The firm earned $5 billion during the quarter, compared to analyst estimates of $4.86 billion. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period last year, the business posted $1.43 earnings per share. Equities research analysts expect that Teva Pharmaceutical Industries Ltd will post $5.26 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Monday, August 22nd were paid a $0.34 dividend. The ex-dividend date was Thursday, August 18th. This represents a $1.36 annualized dividend and a dividend yield of 2.69%.

A number of brokerages have issued reports on TEVA. Jefferies Group cut their target price on Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating on the stock in a research report on Thursday, July 14th. RBC Capital Markets set a $71.00 price target on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Sunday, September 11th. Mizuho reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, July 25th. Wells Fargo & Co. reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Tuesday, May 31st. Finally, Leerink Swann reissued an “outperform” rating and set a $66.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday, August 16th. Seven investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $67.54.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.